Each year there are 70,000 new hip fractures in the UK, with an ongoing annual cost to health and social care services of £3 billion. After this injury, mobility and independence are so badly affected that one in six people never return home. This downward spiral of immobility and dependence contributes to a quarter of people dying within one year of the injury. National mobility targets have been set for hospitals. Firstly patients should be helped out of bed within 48 ...

GO TO STUDY

Hospital-acquired thrombosis (HAT) is defined as any VTE within 90 days of hospital admission, encompassing both deep vein thrombosis (DVT) and pulmonary embolism (PE). HAT represents a significant cause of preventable death, with over 12,000 people dying each year from hospital-associated VTE in the UK. Previous studies report that the risk of untreated high-risk surgical patients developing HAT is as high as 40-60% in orthopaedic patients and 15-40% in general surgery patients. For these patients at highest risk of VTE, key ...

GO TO STUDY

Inherited Cardiac Conditions (ICCs) are a collection of medical disorders that are associated with life-threatening heart rhythm and heart muscle adnormalities. They demonstrate a familial tendency, and a number of disease-causing gene mutations have already been identified. However, a significant proportion of affected families remain with no associated disease-causing mutation; some families have unexplained differences in the severity or type of disorder that different individuals with the same mutation demonstrate. This represents a knowledge gap that this study aims to ...

GO TO STUDY

This Phase III, multi-center, open-label, sponsor-blinded, randomized study is designed to evaluate the efficacy and safety of AZD0901 compared to Investigator’s choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2, and the clinical performance of the investigational IVD. As part of this combined approach, t he efficacy analyses from this study will also provide the basis to evaluate the clinical performance of Ventana CLDN18.2 (SP455) IHC assay (prototype assay and/or validated assay ...

GO TO STUDY

In 2016, 11,563 women died from breast cancer in the UK. Most would have been prescribed hormone therapy (HT); sometimes known as endocrine therapy, which blocks the effect of oestrogen on breast cancer cells. HT is prescribed as a daily tablet, usually for at least five years and often up to 10 years. When women stop taking HT prematurely, or don’t take it as prescribed (known as “poor adherence”), they have up to a three times higher chance of the ...

GO TO STUDY

BI 690517 is an aldosterone synthase inhibitor and participants will be randomised 1:1 (using a minimisation algorithm) to active of placebo BI 690517 in addition to study supplied empagliflozin 10mg daily.

GO TO STUDY

This protocol includes 2 independent, multicenter, randomized, double-blind, placebo-controlled Phase 3 studies (Study 1 and Study 2) to assess the efficacy and safety of MK 7240 in participants of any sex/gender aged 16 to 75 (inclusive) with moderately to severely active CD. While this “master” protocol includes common operational elements for both Study 1 and Study 2, randomization, data collection, statistical analyses, and data reporting will be conducted for each study independently. Each study has its own objectives and ...

GO TO STUDY

Approximately 420 eligible participants will be randomized in a 1:1 ratio to aficamten or placebo. Doses of 5, 10, 15, or 20 mg aficamten or matching placebo will be administered in an escalating manner using echocardiography to guide dose titration. Randomization will be stratified by persistent atrial fibrillation and presence of intracavitary obstruction. The study will consist of 2 parts: Part 1 will be comprised of Day 1 to Week 36 and Part 2 will be comprised of Week 36 to ...

GO TO STUDY

This is a global, multicenter, randomized, open-label, Phase 2/3 study in subjects with platinum-resistant, high-grade ovarian, primary peritoneal, or fallopian tube cancer who have received at least 1 and no more than 3 prior systemic lines of anticancer therapy. In this operationally seamless design, data from Phase 2 will not be utilized for the primary analysis in Phase 3 to strictly control the type I error in Phase 3. Phase 2 Study Design The Phase 2 part of this study is designed ...

GO TO STUDY

Behçet's disease (BD) is an inflammatory condition that causes damages of the blood vessels affecting many parts of the body. The disease is characterized by intermittent symptoms of varying severity across almost all organ systems and oral ulcers, considered the most common sign at the onset of BD and are observed in nearly every patient The treatment of BD is generally based on experience, and the drug of choice is based on specific clinical signs and symptoms in each patient. The ...

GO TO STUDY